CIB2 induced tumor growth and gefitinib resistance by inhibiting cell apoptosis and enhancing EMT in NSCLC, and CIB2 could be applied as a novel biomarker for diagnosis of drug resistance of lung cancer. Here, CIB2 is linked to non-small cell lung carcinoma.